Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Operating Income Loss of $2.16 billion for the year ending 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +811.9% in Operating Income Loss from 2024 to 2025.
- This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $895.00 million | Q2 2017: -$5.74 billion | Q3 2017: $378.00 million | Q1 2018: $1.53 billion | Q2 2018: -$14.00 million | Q3 2018: $16.00 million | Q1 2019: $134.00 million | Q2 2019: -$644.00 million | Q3 2019: -$81.00 million | Q1 2020: $191.00 million | Q2 2020: $173.00 million | Q3 2020: -$4.34 billion | Q1 2021: $434.00 million | Q2 2021: $582.00 million | Q3 2021: $623.00 million | Q1 2022: -$713.00 million | Q2 2022: -$967.00 million | Q3 2022: $424.00 million | Q4 2022: -$940.00 million | Q1 2023: -$13.00 million | Q2 2023: -$654.00 million | Q3 2023: $344.00 million | Q1 2024: -$218.00 million | Q2 2024: -$5.00 million | Q3 2024: -$51.00 million | Q1 2025: $519.00 million | Q2 2025: $455.00 million | Q3 2025: $882.00 million.
- Over the full 18 years of available data (2008 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Operating Income Loss has grown by 88.4%.
- Historical annual values: Fiscal year 2025: $2.16 billion | Fiscal year 2024: -$303.00 million | Fiscal year 2023: $433.00 million | Fiscal year 2022: -$2.20 billion | Fiscal year 2021: $1.72 billion | Fiscal year 2020: -$3.57 billion | Fiscal year 2019: -$443.00 million | Fiscal year 2018: -$1.64 billion | Fiscal year 2017: -$17.48 billion | Fiscal year 2016: $2.15 billion | Fiscal year 2015: $3.35 billion | Fiscal year 2014: $3.95 billion | Fiscal year 2013: $1.65 billion | Fiscal year 2012: $2.21 billion | Fiscal year 2011: $3.11 billion | Fiscal year 2010: $3.87 billion | Fiscal year 2009: $2.41 billion | Fiscal year 2008: $1.15 billion.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: